Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.37 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | KIF11 | P52732 | 4/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.37 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | CTSG | P08311 | 1/20 | 0.37 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.37 |
| ▸ | CMA1 | P23946 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1635912 | 0.97 | POLB (0.44) | POLBCYP1A2CYP3A4RECQLKIF11 | |
| Bromide SCHEMBL1634841 | 0.88 | CYP1A2 (0.42) | CYP1A2CYP3A4RECQLKIF11MAPK1 | |
| SCHEMBL1633683 | 0.84 | CYP1A2 (0.44) | CYP1A2CYP3A4RECQLKIF11MAPK1 | |
| SCHEMBL4958072 | 0.74 | KIF11 (0.45) | POLBKIF11CYP2C19CNR2PRSS1 | |
| SCHEMBL819687 | 0.68 | TRPA1 (0.51) | CYP1A2CYP3A4RECQLCYP2C9CYP2C19 | |
| SCHEMBL415700 | 0.68 | CYP1A2 (0.54) | CYP1A2CYP3A4RECQLKIF11MAPK1 | |
| Bromide SCHEMBL1634342 | 0.68 | DRD3 (0.47) | KIF11KCNH2OPRM1OPRD1MRGPRX2 | |
| SCHEMBL27666824 | 0.68 | CTSK (0.49) | MAPK1CNR2SMN1; SMN2HIF1A | |
| Bromide SCHEMBL11786187 | 0.67 | CYP1A2 (0.44) | CYP1A2CYP3A4RECQLMAPK1CYP2C9 | |
| Bromide SCHEMBL11785436 | 0.67 | SLC6A2 (0.45) | CYP1A2CYP3A4RECQLKIF11MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932290-B2 | Method for the treatment of metabolic disorders | WELLSTAT BIOLOGICS CORPORATION (US) | 2011-04-26 | — | — | US | disclosed |
| EP-2266946-A2 | Compound For The Treatment Of Metabolic Disorders | Wellstat Therapeutics Corporation (US) | 2010-12-29 | — | — | EP | disclosed |
| US-20100087541-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2010-04-08 | — | — | US | disclosed |
| EP-1618086-B1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORP (US) | 2009-12-02 | — | — | EP | disclosed |
| US-7615575-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-11-10 | — | — | US | disclosed |
| US-7605181-B2 | Method for the treatment of metabolic disorders | Wellstat Therapeutics Orporation (US) | 2009-10-20 | — | — | US | disclosed |
| US-7361686-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2008-04-22 | — | — | US | disclosed |
| US-20080015254-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2008-01-17 | — | — | US | disclosed |
| US-20070105955-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2007-05-10 | — | — | US | disclosed |
| EP-1618086-A4 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORP (US) | 2007-05-09 | — | — | EP | disclosed |
| EP-1601251-A4 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORP (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060247309-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2006-11-02 | — | — | US | disclosed |
| EP-1618086-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2006-01-25 | — | — | EP | disclosed |
| EP-1601251-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004093806-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004073611-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087541-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | CPT1B, FABP1, CPT1A | CHRM3 735/4885ADRA1A 442/4885POLB 2060/4885 |
| US-20080015254-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | CPT1B, FABP1, CPT1A | CHRM3 735/4885ADRA1A 442/4885POLB 2060/4885 |
| US-20070105955-A1 | Compounds for the treatment of metabolic disorders | CPT1B, FABP1, CPT1A | CHRM3 715/4885ADRA1A 450/4885POLB 1861/4885 |
| US-20060247309-A1 | Compounds for the treatment of metabolic disorders | CPT1B, CPT1A, FABP1 | CHRM3 1810/4885ADRA1A 819/4885POLB 2184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.